Disease · MONDO_0005324

seasonal allergic rhinitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. seasonal allergic rhinitis. Diseases, record MONDO_0005324. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005324

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: seasonal allergic rhinitis; Open Targets
Open Targets ID: MONDO_0005324; Open Targets
Other names: Allergic Rhinitides, Seasonal, Allergic Rhinitis, Seasonal, Allergies, Pollen, Allergy, Pollen, Fever, Hay, Hayfever, Pollen Allergies, Pollen Allergy, Pollinoses, Pollinosis, Rhinitides, Seasonal Allergic, Rhinitis, Allergic, Seasonal, Rhinitis, Seasonal Allergic, Seasonal Allergic Rhinitides, hay fever; Open Targets
MeSH: D006255; MeSH
NCI Thesaurus: C92188; NCI Thesaurus
Highest stage of its drugs: Approval, for 48 of its 88 drugs, from DailyMed, EMA Human Drugs and TTD; Open Targets

Drugs88

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MOMETASONE FUROATE	CHEMBL1161	Small molecule	Approval	DailyMed	32	29	28	Drugs and targets
FLUTICASONE PROPIONATE	CHEMBL1473	Small molecule	Approval	DailyMed	28	26	25	Drugs and targets
AZELASTINE HYDROCHLORIDE	CHEMBL1200809	Small molecule	Approval	DailyMed	28	18	18	Drugs and targets
MONTELUKAST	CHEMBL787	Small molecule	Approval	DailyMed	17	16	16	Drugs and targets
FLUTICASONE FUROATE	CHEMBL1676	Small molecule	Approval	EMA Human Drugs	14	12	12	Drugs and targets
CICLESONIDE	CHEMBL2040682	Small molecule	Approval	DailyMed	12	11	11	Drugs and targets
DESLORATADINE	CHEMBL1172	Small molecule	Approval	DailyMed and EMA Human Drugs	34	7	7	Drugs and targets
LORATADINE	CHEMBL998	Small molecule	Approval	DailyMed	22	7	7	Drugs and targets
OLOPATADINE HYDROCHLORIDE	CHEMBL1719	Small molecule	Approval	DailyMed	8	6	6	Drugs and targets
PSEUDOEPHEDRINE	CHEMBL1590	Small molecule	Approval	DailyMed and EMA Human Drugs	7	5	5	Drugs and targets

1 to 10 of 88

See all 88 drugs

Targets37

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HRH1	Histamine H1 receptor	34	Histamine H1 receptor antagonist; Histamine H1 receptor inverse agonist	Approval	https://conductscience.org/library/genes/3269	Drugs and targets
NR3C1	Glucocorticoid receptor	11	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
ADRA1A	Adrenergic receptor	7	Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha-1 agonist	Approval	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor	7	Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha-1 agonist	Approval	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor	7	Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha-1 agonist	Approval	https://conductscience.org/library/genes/146	Drugs and targets
ADRA2A	Adrenergic receptor	5	Adrenergic receptor agonist; Adrenergic receptor alpha agonist	Approval	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor	5	Adrenergic receptor agonist; Adrenergic receptor alpha agonist	Approval	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor	5	Adrenergic receptor agonist; Adrenergic receptor alpha agonist	Approval	https://conductscience.org/library/genes/152	Drugs and targets
CHRM3	Muscarinic acetylcholine receptor M3	4	Muscarinic acetylcholine receptor M3 antagonist	Approval	https://conductscience.org/library/genes/1131	Drugs and targets
CHRM2	Muscarinic acetylcholine receptor M2	3	Muscarinic acetylcholine receptor M2 antagonist	Approval	https://conductscience.org/library/genes/1129	Drugs and targets

1 to 10 of 37

See all 37 targets

Trials165

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00578929	Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients	Phase 3	2,388	2010-02-09	Seasonal Allergic Rhinitis	OLOPATADINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00883168	A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies	Phase 3	1,791	2012-09-07	Seasonal Allergic Rhinitis	AZELASTINE HYDROCHLORIDE, FLUTICASONE PROPIONATE	Its record names the disease	ClinicalTrials.gov
NCT00979901	Montelukast in Patients With Seasonal Allergic Rhinitis - Spring 2000 Study (MK-0476A-162)(COMPLETED)	Phase 3	1,577	2010-06-08	Seasonal Allergic Rhinitis	MONTELUKAST	Its record names the disease	ClinicalTrials.gov
NCT02246920	Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients	Phase 3	1,474	2023-06-08	Seasonal Allergic Rhinitis	FLUTICASONE PROPIONATE	Its record names the disease	ClinicalTrials.gov
NCT00972738	Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235)	Phase 3	1,214	2010-06-16	Seasonal Allergic Rhinitis	LORATADINE, MONTELUKAST	Its record names the disease	ClinicalTrials.gov
NCT02631551	Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)	Phase 3	1,180	2018-08-15	Seasonal Allergic Rhinitis	MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT02870205	Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)	Phase 3	1,176	2018-04-06	Seasonal Allergic Rhinitis (SAR)	MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT02318303	To Study GSP 301 in Patients With Seasonal Allergic Rhinitis	Phase 2	1,111	2017-06-28	Seasonal Allergic Rhinitis	MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00963469	Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240)	Phase 3	1,079	2010-06-09	Seasonal Allergic Rhinitis	LORATADINE, MONTELUKAST	Its record names the disease	ClinicalTrials.gov
NCT02230696	Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic Rhinitis	Phase 3	951	2021-03-15	Seasonal Allergic Rhinitis	AZELASTINE HYDROCHLORIDE, FLUTICASONE PROPIONATE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 165

See all 165 trials

Comparisons in its trials31

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Fluticasone Propionate Nasal Spray vs Placebo Nasal Spray: serious adverse events	0 of 314	0 of 312	626	NCT01817790	Trial comparisons
Levocetirizine vs Placebo: serious adverse events	1 of 285	0 of 293	578	NCT00653224	Trial comparisons
Astepro 0.15% vs Placebo: serious adverse events	0 of 266	0 of 266	532	NCT00660829	Trial comparisons
Astepro 0.15% vs Placebo: serious adverse events	0 of 251	0 of 255	506	NCT00824473	Trial comparisons
Astepro 0.15% vs Placebo: serious adverse events	0 of 238	0 of 242	480	NCT00719862	Trial comparisons
Desloratadine vs Placebo: Number of Participants Who Discontinue Study Drug Due to an AE	2 of 223	2 of 225	448	NCT02320396	Trial comparisons
Desloratadine vs Placebo: Number of Participants Who Experience at Least One Adverse Event (AE)	19 of 223	13 of 225	448	NCT02320396	Trial comparisons
Desloratadine vs Placebo: serious adverse events	1 of 223	0 of 225	448	NCT02320396	Trial comparisons
GSP 301 NS vs Placebo NS: deaths from any cause	0 of 225	0 of 221	446	NCT03463031	Trial comparisons
GSP 301 NS vs Placebo NS: serious adverse events	0 of 225	1 of 221	446	NCT03463031	Trial comparisons

1 to 10 of 31

See all 31 comparisons in its trials

Papers from its trials49

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37394178	RESULT	1	PubMed
30027002	RESULT	1	PubMed
23562197	RESULT	1	PubMed
22370531	RESULT	1	PubMed
21439168	RESULT	2	PubMed
21261661	RESULT	1	PubMed
21130386	RESULT	1	PubMed
21067660	RESULT	1	PubMed
20434199	RESULT	1	PubMed
19449366	RESULT	1	PubMed

1 to 10 of 49

See all 49 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005324

GET https://conductscience.org/api/diseases/v1/MONDO_0005324/drugs?page=2

API reference For AI assistants